Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The lineup includes ICOTYDE, an oral treatment for plaque psoriasis. The company has yet to disclose sales figures for the medication. How much the drug can ultimately add to J&J remains an open question. Anyone purchasing shares today takes on that unknown before the answer is in.

J&J Expects ICOTYDE To Become A Major Drug

During the third-quarter 2026 earnings call on October 13, 2026, J&J was asked if it sees ICOTYDE as a $10 billion-plus asset. Management responded that the drug is off to a great start. Executives foresee ICOTYDE…